Interessant summit PCI Biotech skal delta på og presentere.
Antar presentasjon blir lagt ut etter morgendagens seanse.
LifeSci Advisors Nordic BioTech Summit
June 29, 2021
7:30 AM-3:00 PMET
The Nordic life science industry has expanded rapidly over the last 20 years, with hundreds of innovative biotechs emerging from large pharmaceutical companies or academic and private research. The five neighboring Nordic nations excel in complementary fields, creating a powerful hub for innovative, entrepreneurial research and development based on a strong talent pool, access to financing, favorable regulations and use of health data. LifeSci Advisors is looking forward to hosting a selection of the Nordic region’s most dynamic biotechs, who will have the opportunity to present their companies to our extensive North American, pan-European and Israeli network of investors and strategic partners.
Agenda for presenting companies to follow, but current panels include :
- Diversifying a Shareholder Base Beyond Home Market
- Overcoming the Challenges of a Dual Listing
- Near Term Outlook for Strategic Partnering
https://web.cvent.com/event/63ec6ced-8c45-4618-847d-e329242d3b59/summary
2021 kan bli ny spending spree i pharma sektoren?
« remain in 2021 as life science deal activity begins to rebound»
Big pharma’s bolt-on craze
Big pharma companies will continue to be major acquirers in the space, said Peter Behner, Global Life Sciences Transactions leader at EY . Smaller, bolt-on transactions had been their main focus last year, and this trend is likely to remain in 2021 as life science deal activity begins to rebound, he said.
One of the key drivers for bolt-on deals is the established companies’ continuous search for innovative assets, Behner said. He noted an increasing share of big pharma’s revenue has come from externally acquired products over the past 20 years, now close to 70% of their total sales on average.
“Big pharma essentially is a huge oven that constantly burns IP; you constantly have to throw new IPs in, because at the tail end, you know your products would lose patent protection and you need new drugs, otherwise, you can’t grow,” he said.